|
|
|
|
|
|
|
|
| |
| |
|
|
 |
|
 |
|
|
|
| |
| THE KINASE PROMISE . . . |
 |
|
| Xcovery is a new biotechnology company spun out from
The Scripps Research Institute by Sherry Snyder (CEO) and Chris
Liang (CSO), with the support of several prominent academic partners.
Mr. Snyder is the founder and former CEO of Genzyme, one
of the world’s most successful biotechnology companies, as well
as the kinase company Upstate Biotechnology, since sold to Serologicals.
Dr. Liang is a co-inventor of Sutent, Pfizer’s lead cancer
drug, and is also the Director of Medicinal Chemistry at the Scripps
Research Institute in Jupiter, Florida. |
|
| Xcovery develops next generation kinase
therapeutics for cancer and inflammatory diseases. Xcovery’s
approach, based on Dr. Liang’s ten years of kinase medicinal
chemistry experience, is to generate lead compounds with greater selectivity, better efficacy, and reduced toxicity, and to do so more rapidly and economically
than current approaches. |
|
| Xcovery best-in-class therapeutics are targeted for self-development as well as partnering
with leading biotechnology and pharmaceutical companies. |
| |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
